The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications.

被引：0
|
作者：
Mitsiades, N
Mitsiades, CS
Richardson, PG
Poulaki, V
Fanourakis, G
Tai, YT
Chauhan, D
Schlossman, R
Munshi, NC
Hideshima, T
Anderson, KC
机构：
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
390
引用
收藏
页码：105A / 106A
页数：2
相关论文
共 50 条
  • [1] The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
    Mitsiades, N
    Mitsiades, CS
    Richardson, PG
    Poulaki, V
    Tai, YT
    Chauhan, D
    Fanourakis, G
    Gu, XS
    Bailey, C
    Joseph, M
    Libermann, TA
    Schlossman, R
    Munshi, NC
    Hideshima, T
    Anderson, KC
    [J]. BLOOD, 2003, 101 (06) : 2377 - 2380
  • [2] The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents
    Ma, MH
    Yang, HH
    Parker, K
    Manyak, S
    Friedman, JM
    Altamirano, C
    Wu, ZQ
    Borad, MJ
    Frantzen, M
    Roussos, E
    Neeser, J
    Mikail, A
    Adams, J
    Sjak-Shie, N
    Vescio, RA
    Berenson, JR
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (03) : 1136 - 1144
  • [3] Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells
    Chauhan, D
    Li, GL
    Podar, K
    Hideshima, T
    Mitsiades, C
    Schlossman, R
    Munshi, N
    Richardson, P
    Cotter, FE
    Anderson, KC
    [J]. BLOOD, 2004, 104 (08) : 2458 - 2466
  • [4] Proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma cells to chemotherapeutic agents and overcomes chemo-resistance through inhibition of the NF-κB pathway.
    Ma, MH
    Parker, KM
    Manyak, S
    Altamirano, CV
    Wu, ZQ
    Borad, MJ
    Roussos, E
    Neeser, J
    Mikail, A
    Frantzen, M
    Adams, J
    Yang, H
    Siak-Shie, N
    Vescio, RA
    Berenson, JR
    [J]. BLOOD, 2001, 98 (11) : 473A - 473A
  • [5] The proteasome inhibitor PS-341 modulates VEGF secretion and activity in multiple myeloma.
    Mitsiades, N
    Mitsiades, CS
    Poulaki, V
    Fanourakis, G
    Chauhan, D
    Munshi, NC
    Hideshima, T
    Anderson, KC
    [J]. BLOOD, 2002, 100 (11) : 815A - 815A
  • [6] The proteasome inhibitor PS-341 is more cytotoxic in myeloma cells adhered to fibronectin.
    Landowski, TH
    Adams, J
    Dalton, WS
    [J]. BLOOD, 2002, 100 (11) : 393B - 393B
  • [7] PS-341 is active in multiple myeloma: Preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies.
    Stinchcombe, TE
    Mitchell, BS
    Depcik-Smith, N
    Adams, J
    Elliott, P
    Shea, TC
    Orlowski, RZ
    [J]. BLOOD, 2000, 96 (11) : 516A - 516A
  • [8] The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
    Hideshima, T
    Richardson, P
    Chauhan, D
    Palombella, VJ
    Elliott, PJ
    Adams, J
    Anderson, KC
    [J]. CANCER RESEARCH, 2001, 61 (07) : 3071 - 3076
  • [9] Proteasome inhibitor PS-341 inhibits human multiple myeloma cell growth in a murine model.
    LeBlanc, R
    Catley, L
    Hideshima, T
    Pien, CS
    Elliott, PJ
    Anderson, KC
    [J]. BLOOD, 2001, 98 (11) : 774A - 774A
  • [10] Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer
    Mack, PC
    Davies, AM
    Lara, PN
    Gumerlock, PH
    Gandara, DR
    [J]. LUNG CANCER, 2003, 41 : S89 - S96
12345